P3.17-03 Survival and Side Effects in Non-Small Cell Lung Cancer Patients Treated with Combination of Chemotherapy and Conformal Radiotherapy

Abstract

Combined modality therapy is standard of care for patients with unrespectable locally advanced non-small cell, however, insufficient data are available regarding what is the best combination of chemotherapy and radiotherapy. s: To evaluate the treatment results, study of 85 patients was randomly assigned to one of the two treatment arms. In the sequential arm, 45 patients had previously received sequential chemotherapy with 4 cycles of carboplatin and etoposide followed by conformal radiotherapy (RT). In the second concurrent arm, 40 patients received concomitant chemotherapy of cisplatine and etoposide and conformal RT, followed by two cycles of consolidation chemotherapy of carboplatine and etoposide. We described all phases of the conformal RT. s: From October 2005 to April 2008, 85 patients were enrolled. The median survival was 13 months for the patients in the sequential arm and 19 months for those in the concurrent treatment arm. The differences were statistically significant (log-rank test p=0.0039) Figure 1. The disease-free survival was 9 months in the sequential arm and 16 months in the concurrent treatment group. The differences were statistically significant (log-rank test p=0.0023). Treatment-related toxicities were assessed according RTOG/EORTC criteria. Acute esophagitis and incidence of neutropenia were higher in the concurrent arm.. Grade 3 esophagitis was characteristic only for concurrent treatment and it was reason for radiotherapy interruption, but no longer than 7 days. s: Given the higher toxicity in the concurrent-consolidation schedule, it should be reserved for patients younger than 70 years, having good performance status and minimal weight loss.